Septerna, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Septerna, Inc. (SEPN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $2.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.77M, a 45.23% increase year-over-year.
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $294.00K, a 39.75% decline year-over-year.
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $825.00K, a 72.93% decline year-over-year.
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.25M, a 159.75% increase year-over-year.
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.78M, a 12.01% decline from fiscal 2024.
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $4.30M, a 3059.56% increase from fiscal 2023.
- Septerna, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $136.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.06M 10-Q · filed 2026-08-10 | $2.88M derived: sum of 3 quarters · filed 2026-08-10 | $4.14M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $294.00K 10-Q · filed 2026-05-11 | $1.12M derived: sum of 2 quarters · filed 2026-05-11 | $2.37M derived: sum of 3 quarters · filed 2026-05-11 | $3.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $825.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.08M derived: sum of 2 quarters · filed 2026-03-09 | $3.29M derived: sum of 3 quarters · filed 2026-08-10 | $3.78M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.47M derived: sum of 2 quarters · filed 2026-08-10 | $2.96M 10-Q · filed 2025-11-10 | $6.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.70M 10-Q · filed 2026-08-10 | $4.75M derived: sum of 3 quarters · filed 2026-08-10 | $5.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $488.00K 10-Q · filed 2026-05-11 | $3.54M derived: sum of 2 quarters · filed 2026-05-11 | $4.02M derived: sum of 3 quarters · filed 2026-05-11 | $3.42M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.53M derived: sum of 2 quarters · filed 2026-03-09 | $2.94M derived: sum of 3 quarters · filed 2026-03-09 | $4.30M 10-K · filed 2026-03-09 |
| 2024-09-30 | $482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$112.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.25M 10-Q · filed 2025-11-10 | $1.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$594.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $767.00K 10-Q · filed 2025-08-11 | $869.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $1.36M 10-Q · filed 2025-05-15 | $1.46M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $136.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $34.00K 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |